Boehringer Ingelheim’s investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF) was granted Breakthrough Therapy Designation by the FDA. BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs).   The efficacy, safety, and tolerabi...